Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

ON 01910

Known as: ON-01910, ON01910 
 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

GlycineSulfones

Narrower (2)

ON 01910.Narigosertib
analogs & derivatives

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.
PURPOSE Squamous cell carcinoma (SCC) of the skin is the leading cause of death in patients with the severe generalized form of… Expand
Is this relevant?
2018
2018
Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option
Inhibition of RAS-RAF-ERK-signaling is a major mechanism mediated by the multi-kinase inhibitors sorafenib and regorafenib, the… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2014
2014
Discovery of (E)-3-((styrylsulfonyl)methyl)pyridine and (E)-2-((styrylsulfonyl)methyl)pyridine derivatives as anticancer agents: synthesis, structure-activity relationships, and biological activities…
ON01910.Na is a highly effective anticancer agent that induces mitotic arrest and apoptosis. Clinical studies with ON01910 in… Expand
  • table 1
  • figure 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
2013
2013
A Novel Anti-Tumor Inhibitor Identified by Virtual Screen with PLK1 Structure and Zebrafish Assay
Polo-like kinase 1 (PLK1), one of the key regulators of mitosis, is a target for cancer therapy due to its abnormally high… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2012
2012
Preclinical Pharmacokinetic and Pharmacodynamic Evaluation of Novel Anticancer Agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for Brain Tumor Chemotherapy
ABSTRACTPurposeTo evaluate a mitotic inhibitor, ON01910.Na, as a potential chemotherapeutic agent for brain tumors using a series… Expand
  • figure 1
  • figure 2
  • table I
  • table II
  • table III
Is this relevant?
2011
2011
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice.
ON01910 is a small molecular weight benzyl styryl sulfone currently under investigation as a novel anticancer agent. The purpose… Expand
  • figure 1
  • figure 2
  • table 1
Is this relevant?
2010
2010
Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
During the preclinical drug discovery process it remains a challenge to enable early elimination of candidate molecules that may… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
Highly Cited
2009
Highly Cited
2009
BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
PURPOSE Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced and metastatic cancers. To… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Review
2009
Review
2009
BI 6727 , APolo-like Kinase Inhibitor with Improved Pharmacokinetic Profile and Broad
Purpose:Antimitotic chemotherapy remains a cornerstone of multimodality treatment for locally advanced andmetastatic cancers.To… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent.
Elevated expression of polo-like kinase1 (Plk1) has been reported in many human tumors, and inhibition of Plk1 activity results… Expand
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE